CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer by Ang, J E et al.
Minireview
CYP17 blockade by abiraterone: further evidence for frequent
continued hormone-dependence in castration-resistant prostate
cancer
JE Ang
1, D Olmos
1,2 and JS de Bono*,1,2
1The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK;
2The Institute of Cancer Research, 15 Cotswold Road, Sutton,
Surrey SM2 5NG, UK
The limited prognosis of patients with castration-resistant prostate cancer (CRPC) on existing hormonal manipulation therapies calls
out for the urgent need for new management strategies. The novel, orally available, small-molecule compound, abiraterone acetate, is
undergoing evaluation in early clinical trials and emerging data have shown that the selective, irreversible and continuous inhibition of
CYP17 is safe with durable responses in CRPC. Importantly, these efficacy data along with strong preclinical evidence indicate that a
significant proportion of CRPC remains dependant on ligand-activated androgen receptor (AR) signalling. Coupled with the use of
innovative biological molecular techniques, including the characterisation of circulating tumour cells and ETS gene fusion analyses, we
have gained insights into the molecular basis of CRPC. We envision that a better understanding of the mechanisms underlying
resistance to abiraterone acetate, as well as the development of validated predictive and intermediate endpoint biomarkers to aid
both patient selection and monitor response to treatment, will improve the outcome of CRPC patients.
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AR-SIGNALLING PATHWAY AS A THERAPEUTIC
TARGET
Although the majority of patients diagnosed with prostate cancer
are cured with definitive primary treatment, prostate cancer
remains the second leading cause of male cancer-related death in
the western world (Ferlay et al, 2007). Despite major advances
made in the management of advanced prostate cancer, attributable
mainly to the introduction of androgen-deprivation therapy (ADT)
with most remissions lasting 2–3 years at best, many patients will
eventually succumb due to the emergence of castration resistance
(Pienta and Bradley, 2006). The centrality of androgens and the
androgen receptor (AR) in castration-resistant prostate cancer
(CRPC) is, paradoxically, echoed by the common, albeit erroneous,
use of the terms ‘hormone resistant’ and ‘androgen independent’.
Indeed, the progression of prostate cancer despite the adminis-
tration of ADT is more a reflection of the ineffectiveness of current
treatments than the disease gaining genuine autonomy from
AR-signalling pathways.
The recognition that the state of androgen resistance is
relative is certainly not new. Clinical experience in the manage-
ment of breast and prostate cancers have clearly illustrated that
repeated hormonal manipulations can be used successfully
(Raghavan and Klein, 2008). Moreover, the importance of non-
gonadal sources of androgens (adrenal and intracrine de novo
synthesis) has long been recognised. In fact, contemporaneous
ADT does not eliminate androgen synthesis within prostate
cancer cells. On the contrary, intraprostatic (in situ and metastatic)
levels of DHT and testosterone have been shown to remain
elevated despite castrate serum levels (Titus et al, 2005).
Additionally, not only is there autonomous overexpression of
enzymes key to the synthesis of androgenic steroids (Stanbrough
et al, 2006), AR-signalling pathways have also been shown to be
persistently activated (Titus et al, 2005). All these point to
the de novo intratumoural synthesis of androgens that could
be critical to driving the progression of castration-resistant
tumours. This may be compounded by the emergence of a
hypersensitive phenotype (likely though AR mutation, amplifica-
tion, and/or AR modulation by signalling pathways) that renders
these cells exquisitely sensitive to extremely low levels of
exogenous androgens (Taplin, 2007). Furthermore, currently
approved antiandrogens, such as bicalutamide, hydroxyflutamide
and nilutamide, have weak agonistic effects in prostate cancers
with mutated or overexpressed AR (Chen et al, 2004), and this
provides a mechanistic explanation for the treatment failure
using these agents as well as the clinical phenomenon of the
‘androgen withdrawal response’. Overall, these data supported the
study of a systemic CYP17 inhibitor to rationally deplete
intratumoural and other extragonadal sources of steroid ligands
to AR and ERa (androgenic and oestrogenic) that may impact
CRPC biology.
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CYP17 in androgenic steroidogenesis
The CYP17 enzyme localises to the endoplasmic reticulum of Leydig
cells in the testis, theca interna region of the ovaries, and zona
fasciculata and reticularis in the adrenal glands. It is a key enzyme in
the generation of androgens and oestrogens in the adrenal glands and
tumour tissue, and works by the catalysis of two independently
regulated steroid reactions, involving 17a-hydroxylase and C17,
20-lyase, in the biosynthesis pathway, as illustrated in Figure 1 (Miller
et al, 1997). The 17a-hydroxylase activity converts pregnenolone to
17a-hydroxypregnenolone and progesterone to 17a-hydroxyproges-
terone, whereas C17,20-lyase converts 17a-hydroxypregnenolone
to dehydroepiandrosterone (DHEA) and 17a-hydroxyprogesterone
to androstenedione (Miller et al, 1997; Auchus, 2004).
Rationale for the safe inhibition of CYP17
In congenital CYP17 deficiencies, the production of cortisol,
androgens and oestrogens is impaired, leading to the lack of sexual
development (Auchus, 2004). Nonetheless, the synthesis of
corticosterone, a weaker glucocorticoid, is preserved. Hence,
patients do not develop symptoms of adrenal insufficiency.
However, higher levels of adrenocorticotrophic hormone (ACTH)
are required before a new steady state is reached, as corticosterone
is a weaker glucocorticoid than cortisol. Raised levels of ACTH
result in a syndrome of secondary mineralocorticoid excess
characterised by fluid overload, hypertension and hypokalaemia
(Figure 1). Fortuitously, this syndrome may be managed effectively
with mineralocorticoid antagonists, with or without low dose
glucocorticoids to suppress ACTH generation. ACTH suppression,
in turn, leads to normalisation of mineralocorticoid levels, and
thence, serum potassium levels and blood pressure.
Prior experience with ketoconazole
Ketoconazole, an antifungal with weak and non-specific CYP17
inhibitory properties, has been extensively used for the ‘off-label’
treatment of advanced CRPC. The effective inhibition of the
14a-demethylase enzyme (that is responsible for its antifungal
properties) occurs at low doses of ketoconazole, whereas much
higher doses are required for the non-specific inhibition of CYP17
(De Coster et al, 1986) and 11b-hydroxylase (Loose et al, 1983), but
this results in neurological, respiratory and hepatic toxicities
which are common and severe, with up to 20% of patients
discontinuing treatment.
Efficacy data from phase II trials have shown that the response
rate by prostate specific antigen (PSA) working group (PSAWG)
criteria (Bubley et al, 1999) with ketoconazole range between
40–62% with a median duration of up to 7 months (Small et al,
1997; Millikan et al, 2001; Figg et al, 2005; Ryan et al, 2007).
The CALGB 9583 phase III study compared antiandrogen
withdrawal alone vs antiandrogen withdrawal plus ketoconazole
400mg thrice daily, resulting in response rates by PSAWG
of 11% vs 27%, respectively, but no difference in overall survival;
the latter observation was thought to be attributable, at least in
part, to a high crossover rate of 82% to the ketoconazole arm
(Small et al, 2004). It was also noted that resistance to ketoconazole
can develop rapidly due to the loss of CYP17 inhibitory effect
(Small et al, 2004). In addition, most prospective studies
incorporate the use of corticosteroids; this does not seem to
reduce toxicities from high-dose ketoconazole and has additionally
complicated the interpretation of the endocrine and antitumoural
effects.
Overall ketoconazole has antitumoural activity in prostate
cancer. Although its specific role in prostate cancer therapeutics
remains debatable, results from studies using it argued for the
potentially important role of more selective and irreversible CYP17
inhibitors.
Preclinical development of abiraterone acetate
The pregnenolone-derived compound, abiraterone (CB7598), was
developed as part of a series of potent, inhibitory 17-(3-pyridyl)
steroids at The Institute of Cancer Research, UK (Barrie et al, 1994;
Potter et al, 1995; Rowlands et al, 1995). The features which set it
apart from the other candidate small molecular inhibitors of the
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Figure 1 Androgen biosynthesis pathway. The physiological effects of abiraterone acetate on steroidogenesis are indicated by arrows next to each steroid
precursor. Abiraterone acetate inhibits 17a-hydroxylase (blunt arrow), causing a decline in serum cortisol and a consequent rise in adrenocorticotrophic
hormone (ACTH) (broken arrow). This, in turn, results in the rise of deoxycorticosterone and corticosterone by approximately 10- and 40-fold, respectively.
The elevated deoxycorticosterone levels result in the expected toxicities of secondary mineralocorticoid syndrome. Abiraterone acetate also inhibits
C17,20-lyase (blunt arrow) resulting in significant declines in dehydroepiandrostenedione (DHEA), androstenedione and testosterone. Aldosterone levels fall
due to suppression of the renin–angiotensin pathway by high levels of deoxycorticosterone. However, there is a four-fold increase in 11-deoxycortisol,
which may be due to the increased ACTH levels driving the partial reversal of the activity of 17a-hydroxylase but not C17,20-lyase.
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bond between positions 16 and 17 of the steroidal skeleton, as
illustrated in Figure 2; these render both potency and selectivity in
CYP17 inhibition to this compound with a Kiapp of o1n M. The
acetate prodrug, CB7630, was recommended for oral dosing due to
its improved bioavailability and favourable pharmacokinetic
profile.
In preclinical toxicology studies, abiraterone reduced the
weights of androgen-dependent organs (prostate, seminal vesicles
and testes) with minimal side effects in other organs when
administered daily.
Phase I studies of abiraterone acetate
First-in-man phase I studies reported that abiraterone acetate was
safe when administered daily for 12 days to men with non-
progressing prostate cancer, and resulted in 450% suppression of
baseline testosterone in non-castrate patients (O’Donnell et al,
2004). However, this effect was transient and was negated by a
compensatory rise in luteinizing hormone levels within 3 days.
Hence, concomitant castration was maintained in subsequent
studies to prevent this.
On the background of the need for an improved means of
depleting androgens, coupled with the presence of a sound
rationale for the safety of continuous inhibition of CYP17,
alongside preliminary evidence for the favourable pharmaco-
kinetic and endocrine profiles of abiraterone acetate, we
performed a phase I clinical trial that has been recently reported
(Attard et al, 2008). This involved the continuous, once-daily
dosing of abiraterone acetate to castrate, chemotherapy-naı ¨ve
patients with CRPC, escalating through five pre-planned dose
levels of 250, 500, 750, 1000 and 2000mg using three-patient
cohorts. This was the first study to show that selective and
continuous inhibition of CYP17 is safe with an associated durable
suppression of serum androgens and oestrogens, as well as durable
antitumour activity. This study was not designed to compare the
antitumour activity of different dose-levels; as no treatment-
related grade 3 or 4 toxicities were encountered and clinical
responses were reported at all dose levels tested, the recommended
phase II dose of 1000mg was selected on the basis of the
observation that the rise of upstream steroids reached a plateau at
doses above 750mg.
The toxicities observed in this study were predominantly due to
secondary mineralocorticoid excess and were controlled with the
mineralocorticoid receptor antagonist, eplerenone; spironolactone
was not used as it has been previously reported to activate AR
(Luthy et al, 1988). In keeping with the described congenital
syndromes of CYP17 deficiency, no patient developed clinically
significant adrenocortical insufficiency. Circulating testosterone
levels in all patients were in the castrate range at baseline
and rapidly became undetectable on treatment at all dose-levels.
Indeed, downstream C-21 androgenic steroids were suppressed to
levels below the lower limit of detection by conventional assays on
treatment.
Overall, 66% of the CRPC patients treated in this study had a
X30% fall in PSA. Declines in PSA were frequently associated with
symptomatic improvement, reduction in serum alkaline phospha-
tase levels, normalisation of elevated lactate dehydrogenase levels
and partial responses by RECIST, with several patients reducing or
discontinuing analgesic (including opiate) use. Significantly,
tumour responses to abiraterone acetate were observed in castrate
patients who had failed several prior lines of AR-targeting therapy
(median of three prior hormonal therapies). Subsequent phase I/II
studies in the UK and US have treated more than 100 patients and
provide additional support to the efficacy of this agent. These
preliminary efficacy data compare favourably with established
second-line ADT and novel molecularly targeting agents, and
mandate further evaluation of this agent in randomised studies.
Phase II/III studies of abiraterone acetate
The results of the phase I studies have led to the phase II evaluation of
abiraterone acetate in CRPC patients in the UK and US (Danila et al,
2008; de Bono et al, 2008; Reid et al, 2008). Specifically, the efficacy of
abiraterone in the settings of both taxane-naı ¨ve and taxane-resistant
CRPC have been examined, the results of which will soon be fully
reported. We have hypothesised that the antitumour activity of
abiraterone acetate will not be significantly affected by previous
treatment with docetaxel and that abiraterone acetate could be an
efficacious treatment in docetaxel-resistant disease. Indeed, prelimin-
ary analyses suggest that this is likely to be true.
A placebo-controlled randomised phase III study with the aim of
securing FDA licensing approval in the post-docetaxel setting is
now open to accrual; 1180 patients will be randomised 2:1 for
abiraterone acetate plus prednisolone (or prednisone) vs pre-
dnisolone (or prednisone) plus placebo, with a primary endpoint
of overall survival. The combination of steroids and abiraterone
acetate should potentially prevent the syndrome of secondary
mineralocorticoid excess and maximise efficacy.
Roles of steroids upstream of CYP17 and abiraterone
resistance
The antitumour activity reported with abiraterone acetate could be
explained, at least in part, by the durable and profound suppression
of serum androstenedione and DHEA, in addition to that of
testosterone and oestradiol (Attard et al, 2008). In keeping with
earlier reports regarding ketoconazole, these data from the phase I
study suggest that higher baseline androstenedione and DHEA levels
are present in patients who responded to abiraterone acetate.
However, unlike ketoconazole, no rise in steroids downstream of
CYP450c17 was observed at disease progression while on abiraterone
acetate, indicating ongoing, irreversible CYP450c17 inhibition.
We hypothesised, a priori, that acquired resistance to abirater-
one acetate could be reversed by suppressing the production of
steroids upstream of CYP17 and this could be achieved by
decreasing ACTH using low dose steroids replacement. Indeed, 4
out of 15 patients (26%) with two of these patients having had
progressive disease earlier on the same dose of dexamethasone,
were successfully salvaged using this approach (Attard et al, 2008)
in the phase I study. Hence, it is possible that elevated levels of
steroids upstream of CYP450c17 could drive the signalling of a
promiscuous, possibly mutated, AR.
Other mechanisms that allow for constitutive AR signalling
include mutated AR; ligandless activation of AR signalling, which
could occur secondary to AR amplification or following phospha-
tase and tensin homologue (PTEN) loss; and/or activation of
translocated ETS gene promoter elements by other steroid
receptors, such as the oestrogen receptor (ER)-a (Taplin, 2007).
In fact, oestradiol activate ER-a binding sites on the TMPRSS2
promoter and the suppression of its production could, in part,
explain the antitumour activity observed with abiraterone acetate
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Figure 2 Chemical structures of abiraterone acetate and abiraterone.
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test these hypotheses.
Robust biomarkers as predictive and intermediate
endpoints
To maximise benefit to patients and accelerate drug approval by
regulatory authorities, the evaluation of robust biomarkers that
can serve as predictive and intermediate end-points is urgently
required in CRPC therapeutic studies. We describe the preliminary
experience we have of the two of the most promising biomarkers
that are emerging in this field; the results of their prospective
verification in larger cohorts of subjects are eagerly awaited.
Fusion of the androgen-regulated gene, TMPRSS2, with ERG
occurs in up to 60% of prostate cancers and is likely to account for
the majority of ETS oncogene rearrangements in prostate cancer
(Attard et al, 2008). We therefore hypothesised that the presence of
a TMPRSS2–ERG fusion gene could indicate dependance on AR
signalling and consequently define a tumour sub-group that is
responsive to abiraterone acetate. In preliminary studies, PSA
decline rate appears to be higher in patients with an ERG
rearrangement in archival trans-rectal biopsy of prostate (TRBP)
samples (five out of six patients in the published phase I study with
an ERG gene rearrangement had a decline in PSA X50%).
However, due to ETS gene rearrangement heterogeneity within a
single prostate, the use of single TRBP cores may miss areas with
ERG rearrangements and fusion of other ETS genes with androgen-
regulated partners can also occur.
We have also recently shown that the presence of X5c i r c u l a t i n g
tumour cells at baseline is associated with a poor outcome and that a
fall in CTC count to o5 following treatment is associated with an
improved prognosis (Olmos et al, 2009). Significantly, five patients
in the phase I study had baseline CTC counts X5 and three of these
patients had their CTC counts reduced to o5 after 12 weeks of
treatment. The aforementioned phase III study is therefore incor-
porating the prospective evaluation of whether changes in CTC
counts post treatment can serve as a robust intermediate endpoint
for overall survival to accelerate drug development for CRPC.
OTHER AGENTS DIRECTLY TARGETING THE
AR-SIGNALLING PATHWAY
In addition to abiraterone and ketoconazole, there are other CYP17
inhibitors that are at various stages of development. VN/124-1,
currently in preclinical development and recently licensed to Tokai
Pharmaceuticals Inc. (Boston, NY, USA), is a 17-benzoimidazole that
has direct inhibitory properties against CYP17 and AR (Handratta
et al, 2005). It has potent antitumour effects in vitro with the ability to
effectively inhibit proliferation of a bicalutamide-resistant prostate
cancer cell lines, which had increased AR expression. Interestingly,
the combination of VN/124-1 with either everolimus or gefitinib
in vitro was also superior to that achieved with the addition of
bicalutamide to either agent, and the VN/124-1 combination effects
were synergistic compared with either agent alone (Schayowitz et al,
2008). It is expected that this agent will be evaluated in the clinical
setting soon.
The novel small molecule AR antagonist, MDV3100, was
rationally designed for its ability to overcome resistance to
conventional bicalutamide in the setting of increased AR expres-
sion (Sawyers et al, 2007). Unlike bicalutamide, MDV3100 inhibits
AR function by blocking nuclear translocation and has no agonist
activity when AR is overexpressed. A first-in-man, multi-center
phase I/II dose-escalation study has been reported with over 50
patients having enrolled when last reported (Scher et al, 2008). In
all, MDV3100 has been well tolerated to date with no significant
adverse events. Significantly, it has resulted in PSA reductions in a
high proportion of evaluable patients and appears to be a
promising candidate for the treatment of progressive CRPC. This
trial is currently ongoing.
To summarise, these agents work directly to reduce or inhibit
AR-mediated signalling by ligand depletion and/or receptor
antagonism. Overall, these data provide further mechanistic and
clinical evidence of the importance and relevance of AR-mediated
signalling pathway in CRPC therapeutics.
FUTURE DIRECTIONS
The promising efficacy of abiraterone acetate stemming from these
early clinical trials in CRPC setting attests to our renewed
recognition of the importance of the AR-signalling pathway in
CRPC biology. It is sobering to realise that up to 70% of patients
who had disease progression on previous lines of hormonal
therapies, are still hormone dependant. Indeed, the recent revision
of misnomers, such as ‘androgen independence’ and ‘hormone
resistance’, by the Prostate Cancer Clinical Trials Working Group
is a reflection of this. The successful reversal of resistance to
abiraterone acetate using low-dose dexamethasone in some
patients also points to the likely importance of steroids upstream
of CYP17, and indicate that AR, although likely mutated and
promiscuous, remains key in this process.
Although the numbers of subjects and biological specimens
involved are small, the evidence from the translational studies
involving ETS gene fusion products and CTCs provide further, albeit
preliminary, molecular biological corroboration of the importance of
AR-mediated signalling mechanisms. These novel molecular plat-
forms may have additional utility in improving our ability to select
patients more likely to benefit from abiraterone acetate treatment.
There are numerous questions emerging from the use of this
compound. For instance, how are the intratumoural androgenic
steroid levels affected by abiraterone acetate? What are the
mechanisms of resistance to it? In what clinical settings ought
the drug be used? With which agents, cytotoxic and novel, should
abiraterone acetate be used? What about the role of abiraterone
acetate in other hormonally driven malignancies?
Overall, these data support the development of further novel
inhibitors of AR signalling. However, sceptics will trumpet the
acknowledgement that we have been in similar positions before
with other ADT modalities. We argue that these new clinical and
translational seeds are being sowed in research soil more fertile
than ever before, enriched by an improved understanding of the
pathways of treatment resistance and the availability of new
technologies in the evaluation of tumour biology. Hence, not only
do we have more effective compounds, there are unparalleled
opportunities for these to be combined with emerging novel
biological agents, supported by the presence of new molecular and
imaging methodologies.
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